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Abstract 
Background: Patients with rheumatoid arthritis (RA) are at a higher cardiovascular (CV) risk in comparison to the 
general population. CV risk associates closely with aortic stiffness. Aim of this exploration was therefore to evaluate 
aortic stiffness in patients with RA and to examine its association with various RA associated parameters as well as 
with traditional CV risk factors.
Methods: Measurements of carotid-femoral pulse wave velocity (cfPWV) were analyzed retrospectively in 38 RA 
patients and 25 controls. We investigated the statistical difference between cfPWV values in the two groups. Further-
more, we analyzed the associations of cfPWV with laboratory and clinical RA parameters including Disease Activity 
Score 28 and its components, rheumatoid factor, cyclic citrullinated peptide antibodies, antinuclear antibodies and RA 
duration. Finally, we explored the relationship of cfPWV with traditional CV risk factors in the RA group.
Results: cfPWV was not significantly higher in RA patients in comparison to controls in an adjusted statistical 
model for confounding factors [−0.587 95 % CI (−1.38 to 0.201), p = 0.144]. Among RA patients there was a statisti-
cally significant correlation of cfPWV with age (rho = 0.544, p = 0.001) and the count of tender joints [0.051 95 % CI 
(0.008–0.207), p = 0.034]. Finally, C-reactive protein associated only marginally with cfPWV [0.105 95 % CI (−0.410 to 
0.003), p = 0.053].
Conclusions: In RA patients the number of tender, rather than swollen joints correlates with stiffness of the aorta, as 
measured through cfPWV. Therefore, RA associated joint pain might play a role in the development of aortic stiffness 
and thus increase CV risk.
Keywords: Rheumatoid arthritis, Aortic stiffness, Joint tenderness, Pain, Cardiovascular risk, Carotid-femoral pulse 
wave velocity
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Background
Autoimmune diseases, such as rheumatoid arthritis (RA), 
correlate with high cardiovascular (CV) risk and high 
morbidity and mortality rates (Abou-Raya and Abou-
Raya 2006). In particular, CV diseases are considered 
to be responsible for the cause of 40–50 % of all deaths 
in patients with rheumatoid arthritis (del Rincón et  al. 
2001). CV risk in the general population can be assessed 
through various markers, one of which is arterial stiff-
ness. Particularly, stiffness of the aortic vasculature is a 
modifiable, independent predictor of CV risk and can 
be measured through carotid femoral pulse wave veloc-
ity (cfPWV) (Laurent et al. 2006). The predictive value of 
this marker concerning CV events has been shown in a 
series of epidemiological studies and cfPWV is nowadays 
characterized as the gold standard for the assessment of 
aortic stiffness (Laurent et al. 2006).
cfPWV gives information about the elasticity of the 
vascular bed among the carotid and the femoral artery 
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(Baulmann et al. 2010). In contrast to parameters such as 
blood pressure, lipids or glucose which match the instan-
taneous intensity of traditional CV risk factors, cfPWV 
reflects the long-term effects of established and unknown 
risk factors together with the individual genetic predis-
position of the patient (Vlachopoulos et al. 2014).
A number of studies reported a statistically significant 
increase of cfPWV in patients with RA in comparison to 
their healthy counter partners (Mäki-Petäjä et  al. 2006; 
Kocabay et  al. 2012; Turkyilmaz et  al. 2013). However, 
some other studies came to the opposite conclusion (Sta-
matelopoulos et  al. 2009; Arida et  al. 2015). Moreover, 
the association between aortic stiffness and different RA 
associated activity and chronicity markers is still some-
what unclear. Aim of this study was therefore to test the 
hypothesis of increased aortic stiffness in a group of RA 
patients in comparison to healthy subjects and to exam-
ine whether there is a correlation of cfPWV with various 
clinical and laboratory RA associated parameters.
Methods
We analyzed retrospectively routine measurements of 
carotid-femoral pulse wave velocity in 38 patients with 
RA and 25 subjects without systemic rheumatic or CV 
diseases. The measurements were conducted in our inpa-
tient rheumatology clinic in Bad Kreuznach, Germany 
as a part of the diagnostic process. Patients with malig-
nancy, pregnancy, age <18 years, active infection and CV 
disease were excluded from the analysis.
All patients with RA met the 2010 American Rheuma-
tism Association (ACR)/European League against Rheu-
matism (EULAR) classification criteria for RA.
Arterial stiffness measurements
The examination protocol of cfPWV was in accordance 
with the recommendations of the expert consensus docu-
ment on arterial stiffness (Laurent et  al. 2006). cfPWV 
was measured as the velocity value calculated through 
the distance between the carotid and femoral artery 
in meters (m) divided by the time that one pulse wave 
needs to cover this distance in seconds (Δs/Δt) (m/s). 
All of the measures were conducted from the author and 
two experienced independent medical assistants using a 
validated non-invasive device (Vicorder®, SMT medical 
GmbH&Co).
cfPWV was assessed three consecutive times in every 
patient and the average value of the measures was docu-
mented and used in the statistical analysis.
During the procedure, a neck pad was placed around 
the neck of the patient. The pad contained a small blad-
der which was placed over the carotid artery. A cuff 
(similar to blood pressure cuffs) was then strapped at the 
thigh of the patient. The bladder of the neck pad and the 
cuff inflated as the test started. After deflation pressure 
waves from the carotid and the femoral artery appeared 
on the screen of a connected laptop. The waves were then 
recorded simultaneously and the time delay between 
carotid and femoral wave was determined.
Data collection
In addition to epidemiological data of both groups (gen-
der, age), clinical and laboratory parameters of chronic-
ity and activity in the RA group such as disease duration, 
disease activity score 28 (DAS28) as well as its compo-
nents [C-reactive protein (CRP), count of tender (TJC) 
and swollen joints (SJC), visual analogue scale (VAS)] 
were examined. Values of ANA, rheumatoid factor and 
anti-CCP-antibodies were also recorded. Finally, the 
presence of traditional CV risk factors such as smoking, 
known arterial hypertension, obesity [Body Mass Index 
(BMI) > 25 kg/m2], hyperlipidemia and type II diabetes of 
the subjects of both groups were documented.
Statistical analysis
The assumption of normality of distribution was evalu-
ated through the Shapiro–Wilk test. Continuous vari-
ables were found to be skewed and therefore presented 
as median (25th and 75th percentiles). Categorical vari-
ables were summarized as absolute (n) and relative (%) 
frequencies.
The difference of cfPWV values between RA patients 
and controls was evaluated through Mann–Witney U test 
as cfPWV was not normally distributed. This test was also 
used to evaluate the association between cfPWV and cat-
egorical variables with two categories. In order to assess 
the correlation between cfPWV and continues character-
istics, the Spearman correlation coefficient was used.
Furthermore, difference of cfPWV values between RA 
patients and controls after controlling for possible con-
founding factors was examined through an appropri-
ate multivariate model. The same statistical model was 
used to check for the effect of confounding factors on the 
established correlations among patients with RA.
Descriptive statistics, regression analyses and tests have 
only been analysed by referring to cases without missing 
values. A probability value of 0.05 was considered statis-
tically significant. We made no formal adjustment for the 
number of performed tests. Thus, the p-values should be 
considered to be exploratory. All statistical calculations 
were performed using the SPSS version 22.0 software 
(SPSS Inc, Chicago, Il, USA).
Results
There was a similar distribution between patients with 
RA and controls regarding gender, arterial hypertension, 
obesity, diabetes mellitus and hyperlipidemia (Table  1). 
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Patients with RA had a higher average age in comparison 
to the control individuals (p = 0.027) and the RA-group 
included more smokers than the control group (34.2 vs. 
12 %, p = 0.041) (Table 1).
Association between group (RA vs. control) and cfPWV
cfPWV average was found to be statistically significantly 
higher in the RA group compared to control group [8.75 
(7.90–9.85) vs 8.10 (7.25–8.65) m/s, p = 0.015] (Fig. 1).
To adjust for factors which had a statistically different 
distribution in the control and RA group (age and nico-
tine use), and therefore could have a confounding effect 
on the results, multiple regressions were performed.
The age-adjusted statistical model revealed that cfPWV 
was only marginally higher in the RA group in com-
parison to the control group [−0.72 95  % CI (−1.50 to 
0.04), p = 0.062]. Moreover, adjustment for both age and 
nicotine use revealed a non-significant statistical differ-
ence between cfPWV in the two groups [−0.587 95 % CI 
(−1.38 to 0.201), p = 0.144]. Associations of cfPWV within RA‑group
Among patients with RA, it was found that cfPWV is 
significantly correlated with patients’ age and RF. This 
means that older patients have higher values of cfPWV 
(rho  =  0.544, p  =  0.001) (Table  2; Fig.  2) and higher 
RF levels are associated with higher cfPWV values 
(rho = 0.369, p = 0.025) (Table 2). Moreover, cfPWV was 
found to be marginally positively correlated with TJC 
(rho =  0.330, p =  0.065) and obesity [8.80 (8.50–10.30) 
vs. 8.60 (7.2–9.15) m/s, p = 0.071] (Tables 2, 3).
However, after adjusting for possible confounders (age, 
obesity) the association between RF and cfPWV did not 
Table 1 Descriptive characteristics by group
The rest of data are presented as absolute (n) and relative frequency (%)
RA rheumatoid arthritis, ANA antinuclear antibodies, RF rheumatoid factor, Anti-
CCP cyclic citrullinated peptide antibodies, DAS28 disease activity score 28, CRP 
C-reactive protein, TJC tender joints count, SJC swollen joints count
* p < 0.05




RA (n = 38) Significance 
(p)
Age (years)a 56 (42, 59.5) 61 (50.50–70.25) 0.027*
Gender (female) 21 (84.0 %) 32 (84.2 %) 0.982
Nicotine use  
(smokers)
3 (12.0 %) 13 (34.2 %) 0.041*
Arterial hyperten-
sion
12 (48.0 %) 18 (47.4 %) 0.960
Obesity 
(BMI > 25 kg/m2)
11 (44.0 %) 19 (50 %) 0.500
Hyperlipidemia 5 (20.0 %) 12 (31.6 %) 0.250
Diabetes mellitus 
(type II)
1 (4.0 %) 5 (13.2 %) 0.214
ANA positivity 
(>1:80)
– 5 (13.9 %) –
BSG (mm/h)a – 25 (14.00–55.50) –
VAS (mm)a – 7 (5.75–8.00) –
CRP (mg/dL)a – 1.1 (0.36–2.62) –
DAS 28 (BSG)a – 5.10 (4.10–5.75) –
DAS 28 (CRP)a – 4.50 (3.45–4.92) –
Disease duration 
(years)a
– 11 (4.00–17.00) –
RF (IU/ml)a – 103 (6.55–322.50) –
CCP (IU/ml)a – 117 (7.25–340.00) –
TJCa – 4.50 (1.00–7.75) –
SJCa – 2 (0.00–4.00) –
Fig. 1 cfPWV in control and group RA. RA rheumatoid arthritis, cfPWV 
carotid-femoral pulse wave velocity. * p < 0.05
Table 2 Association between  quantitative patients’ char-
acteristics and cfPWV in RA patients
Spearman rho was used
RA rheumatoid arthritis, CRP C-reactive protein, ESR erythrocyte sedimentation 
rate, RF rheumatoid factor; Anti-CCP cyclic citrullinated peptide antibodies, TJC 
tender joints count, SJC swollen joints count, VAS visual analogue scale, DAS28 
disease activity score 28
* p < 0.05
‡ in parentheses p values adjusted for age and obesity by multiple regression
Rho Significance (p)
Age 0.544 0.001* (−)
Disease duration 0.021 0.903 (0.913)‡
CRP −0.027 0.876 (0.053)‡
ESR −0.031 0.859 (0.170)‡
RF 0.369 0.025*(0.462)‡
Anti-CCP 0.142 0.401 (0.345)‡
TJC 0.330 0.065 (0.034*)‡
SJC −0.065 0.713 (0.744)‡
VAS 0.117 0.509 (0.763)‡
DAS28 (ESR) 0.191 0.331 (0.658)‡
DAS28 (CRP) 0.213 0.266 (0.499)‡
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remain statistically significant (p = 0.462) (Table 2). On 
the contrary, the statistical significance of the associa-
tion between cfPWV and TJC increased [0.051 95 % CI 
(0.008–0.207), p = 0.034] (Table 2).
Control of all results through adjustment for the 
same confounding factors showed marginal correla-
tions of cfPWV with CRP [0.105 95  % CI (−0.410 to 
0.003), p =  0.053] and arterial hypertension [0.566 95 % 
CI (−0.039 to 2.179), p  =  0.059]. Finally, gender, ANA 
positivity, nicotine use, hyperlipidemia, diabetes, disease 
duration, ESR, anti-CCP, SJC, VAS, DAS28 (ESR) and 
DAS28 (CRP) did not significantly correlate with cfPWV 
in the adjusted statistical models (all p > 0.05, Tables 2, 3).
Conclusions
Pain and aortic stiffness
The novel information of this exploration is the deter-
mined association between cfPWV and TJC in patients 
with RA. To our knowledge, there are no published stud-
ies in which the relationship between aortic stiffness and 
isolated parameters of the DAS28 in RA patients were 
investigated. Interestingly enough, cfPWV did not corre-
late with other parameters of disease activity such as SJC, 
VAS, ESR. The association between CRP and cfPWV was 
statistically marginal.
These results might reveal a closer association of 
cfPWV with joint tenderness and pain than with the acute 
joint-located inflammation in the course of arthritis.
It has been postulated that patients with RA show an 
increased sensibility to noxious stimulation (hyperalge-
sia) at both disease-affected and—non-affected regions 
(Wendler et  al. 2001; Leffler et  al. 2002; Edwards et  al. 
2009). RA is characterized from an altered pain process-
ing in the central nervous system, which is suggested 
through the typical for this disease autonomic dysfunc-
tion and bilateral involvement (Edwards et  al. 2009). 
Additionally, peripheral sensitization of primary afferent 
nociceptive neurons in inflamed sites plays an important 
role in the development of pain symptoms. Responsible 
for this sensitization are various proinflammatory and 
nociceptive molecules such as cytokines, prostaglandin, 
neuropeptides and bradykinin. These components are 
locally produced through inflamed tissue and initiate the 
process of pain transmission (Sprott 2008).
On the other hand, acute pain has been linked to 
hyperactivity of the sympathetic nervous system (SNS) 
(Pickering 2003). Particularly, pain stimuli can lead to a 
significant increase of both muscle sympathetic nerve 
activity (MSNA) and blood pressure (Fagius et  al. 1989; 
Fig. 2 Association between cfPWV (m/s) and age (years) in RA 
patients. RA rheumatoid arthritis, cfPWV carotid-femoral pulse wave 
velocity. ** p < 0.01
Table 3 Associations between qualitative patients’ charac-
teristics and cfPWV (m/s) in RA patients
Mann–Witney U test was used
RA rheumatoid arthritis, cfPWV carotid-femoral pulse wave velocity, ANA 
antinuclear antibodies, BMI body mass index





 Male 8.55 (8.20–8.93) 0.471 (0.598)‡
 Female 8.80 (7.63–10.00)
ANA
 Positive (>1:80) 8.70 (8.00–9.60) 0.993 (0.768)‡
 Negative 8.80 (7.10–10.50)
Nicotine
 Non-smokers 8.70 (7.66–9.75) 0.937 (0.617)‡
 Smokers 8.70 (8.05–9.45)
Arterial hypertension
 No 8.60 (7.00–9.30) 0.176 (0.059)‡
 Yes 8.75 (8.50–10.00)
Obesity (BMI > 25 kg/m2)
 Non-obese 8.60 (7.20–9.15) 0.071 (−)‡
 Obese 8.80 (8.50–10.30)
Hyperlipidemia
 No 8.75 (8.05–9.30) 0.867 (0.424)‡
 Yes 8.90 (7.45–10.23)
Diabetes mellitus (type II)
 No 8.60 (7.63–9.53) 0.182 (0.234)‡
 Yes 9.30 (8.20–12.90)
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Nordin and Fagius 1995). However, MSNA has been 
shown to associate independently of blood pressure 
with aortic stiffness in healthy individuals (Swierblewska 
et  al. 2010). SNS-activation might promote arterial wall 
changes (fibrosis, growth of vascular muscles), which 
lead to an increase of arterial stiffness (Swierblewska 
et al. 2010). Moreover, SNS can cause an increase of aor-
tic stiffness through its interaction with the renin-angi-
otensin-aldosterone system (Mancia et al. 2006). Finally, 
SNS-hyperactivity has been linked to endothelial dys-
function (Sverrisdóttir et  al. 2010), which although dis-
tinct in terms of pathophysiology, cannot be completely 
separated from arterial stiffness (Nigam et al. 2003).
Summarizing, there might be a pathophysiological 
link between pain and the development of aortic stiff-
ness through the effects of increased MSNA on the aortic 
vasculature.
Until now, the relationship between aortic stiffness 
and pain has been examined in studies which how-
ever included patients without the burden of a systemic 
inflammatory rheumatic disease (Lee et  al. 2011;  Kim 
et al. 2010; Vizzardi et al. 2014; Jin et al. 2015). Interest-
ingly, female patients with fibromyalgia syndrome had 
statistically higher values of brachial ankle pulse wave 
velocity (baPWV, a marker of peripheral arterial stiffness) 
in comparison to their healthy counter partners  (Lee 
et al. 2011). The authors implied a catecholamine associ-
ated activation of the autonomic nervous system, which 
led to an increase of arterial stiffness through endothelial 
impairment (Wittstein et al. 2005). The same marker was 
also found to be increased in patients with lumbar disc 
herniation (Jin et al. 2015). According to the authors, one 
of the main reasons for the increase of arterial stiffness in 
those patients was reduced physical activity.
Furthermore, increased augmentation index (indi-
rect marker of arterial stiffness) and baPWV as well as 
endothelial dysfunction have been reported in patients 
with migraines (Jiménez Caballero and Muñoz Escudero 
2013; Ikeda et al. 2011). Nevertheless, in both studies the 
increase of arterial stiffness was not linked to pain and its 
pathophysiological effects. Particularly, in the article of 
Jiménez Caballero and Muñoz Escudero (2013) the quali-
tative reduction and loss of function of endothelial pro-
genitor cells, was among others discussed as a cause of 
impaired endothelial function in patients with migraine 
(Lee et al. 2008).
RA‑associated parameters and aortic stiffness
Our analysis showed higher mean cfPWV values in 
the RA group in comparison to the control group. The 
results however, did not remain statistically significant 
after controlling for possible confounding factors. Other 
researchers found cfPWV to be increased in patients 
with RA in comparison to healthy individuals (Mäki-
Petäjä et al. 2006; Kocabay et al. 2012; Turkyilmaz et al. 
2013). On the other hand, cfPWV was not found to be 
statistically different in a population of RA patients who 
were free of CV risk factors when compared to a group 
of age and gender matched healthy controls (Arida et al. 
2015). Furthermore, in another study cfPWV was found 
to be only statistically marginally increased in patients 
with RA in comparison to controls after adjustment for 
confounding factors (Stamatelopoulos et al. 2009). These 
conflicting data could be due to heterogeneity of study 
protocols regarding the amount, age and CV risk factors 
of examined RA patients and control subjects. A further 
explanation could be provided through differences in 
administered immunosuppressant therapies throughout 
the years, since new RA directed biological drugs lead to 
a reduction of arterial stiffness (Mäki-Petäjä et  al. 2006; 
Galarraga et al. 2009; Protogerou et al. 2011; Vassilopou-
los et al. 2015).
Our exploration did not reveal statistically signifi-
cant correlations between cfPWV and anti-CCP-anti-
bodies, RF, ANA or disease duration. The presence of 
anti-CCP-antibodies has been shown to correlate with 
subclinical vasculopathy (Szekanecz et  al. 2007). Anti-
CCP-positive-patients show an increase of carotid intima 
media thickness (cIMT), which is as a marker of subclini-
cal arteriosclerosis (Gerli et al. 2007; Arnab et al. 2013). 
Furthermore, positivity for anti-CCP is described to be 
a risk factor for the occurrence of an ischemic cardiac 
disease (Arnab et  al. 2013). Even though anti-CCP-pos-
itive patients possess a higher CV risk, there are, to our 
knowledge, no data to support a direct correlation of this 
antibody with cfPWV (Pieringer et al. 2010; Provan et al. 
2011). The presence of RF has been shown to associate 
with higher cIMT values and endothelial dysfunction in 
patients with RA (Rojas-Villarraga et al. 2008; Sahari et al. 
2014), but not directly with aortic stiffness (Mäki-Petäjä 
et al. 2006). We are not aware of studies who examined 
the relationship between ANA and cfPWV. Finally, our 
findings regarding the missing association between aortic 
stiffness and RA disease duration are in agreement with 
other RA/cfPWV studies (Mäki-Petäjä et al. 2006; Provan 
et al. 2011; Li et al. 2013).
The present exploration has some limitations: First 
of all, the low number of patients and control subjects 
may limit the validity of the results. However, a lot of 
published cfPWV studies included similar amount of 
subjects. Secondly, the presence of cardiovascular risk 
factors in both groups may have had a confounding effect 
on the results. Despite the fact that adjusted statistical 
analyses for some of the possible confounders were con-
ducted, the outcomes of the study should be interpreted 
cautiously.
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In conclusion, we report for the first time that aortic 
stiffness can correlate with the count of tender joints in 
patients with RA. The association between joint tender-
ness and aortic stiffness, if proven, could influence future 
treatment decisions in clinical practice. More studies are 
needed, in order to verify this finding and to fully under-
stand the mechanisms behind it.
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